Literature DB >> 8738830

Management of benign and aggressive intracranial meningiomas.

E W Akeyson1, I E McCutcheon.   

Abstract

Usually considered benign tumors, meningiomas can display aggressive behavior characterized by multiple recurrences and invasion of the brain, dura, and adjacent bone. The aggressive or malignant phenotype is difficult to characterize due to the broad spectrum of behaviors exhibited by meningiomas. Recent classification schemes based on features of anaplasia rather than histopathology have been used successfully to identify meningiomas that exhibit features of the aggressive phenotype. Some such tumors can be identified preoperatively by radiographic characteristics. Surgery is the cornerstone of treatment for all types of meningiomas. Conventional radiation therapy is beneficial for patients with recurrent (or incompletely resected) benign meningiomas and is recommended for those with aggressive and malignant meningiomas. Stereotactic radiation and interstitial brachytherapy are useful in some refractory or recurrent meningiomas. Traditional chemotherapeutic agents are not very effective against meningiomas, but hormonal manipulation is under study for patients with inoperable tumors or those who are medically unsuitable for surgery.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8738830

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  15 in total

Review 1.  Fractionated radiotherapy for intracranial meningiomas.

Authors:  Vinai Gondi; Wolfgang A Tome; Minesh P Mehta
Journal:  J Neurooncol       Date:  2010-09-01       Impact factor: 4.130

2.  RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth.

Authors:  Shakuntala Kondraganti; Christopher S Gondi; Ian McCutcheon; Dzung H Dinh; Meena Gujrati; Jasti S Rao; William C Olivero
Journal:  Int J Oncol       Date:  2006-06       Impact factor: 5.650

3.  Treatment-related secondary cancer in malignant meningiomas: a population-based study.

Authors:  Xuhui Bao; Lanfang Cao; Hailan Piao; Liyi Xie
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-08       Impact factor: 4.553

Review 4.  Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.

Authors:  Leland Rogers; Igor Barani; Marc Chamberlain; Thomas J Kaley; Michael McDermott; Jeffrey Raizer; David Schiff; Damien C Weber; Patrick Y Wen; Michael A Vogelbaum
Journal:  J Neurosurg       Date:  2015-01       Impact factor: 5.115

5.  Hydroxyurea chemotherapy for unresectable or residual meningioma.

Authors:  H B Newton; M A Slivka; C Stevens
Journal:  J Neurooncol       Date:  2000-09       Impact factor: 4.130

6.  Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell line.

Authors:  Shakuntala Kondraganti; Christopher S Gondi; Meena Gujrati; Ian McCutcheon; Dzung H Dinh; Jasti S Rao; William C Olivero
Journal:  Int J Oncol       Date:  2006-07       Impact factor: 5.650

7.  Definitive embolization of meningiomas. A review.

Authors:  B T Bateman; E Lin; J Pile-Spellman
Journal:  Interv Neuroradiol       Date:  2005-10-25       Impact factor: 1.610

8.  Hydroxyurea treatment of meningiomas: a pilot study.

Authors:  Gabriel J Weston; Andrew J Martin; Ghulam J Mufti; Anthony J Strong; Michael J Gleeson
Journal:  Skull Base       Date:  2006-08

9.  Predictors of Treatment Response and Survival Outcomes in Meningioma Recurrence with Atypical or Anaplastic Histology.

Authors:  Muhammad O Chohan; Christopher T Ryan; Ranjodh Singh; Ryan M Lanning; Anne S Reiner; Marc K Rosenblum; Viviane Tabar; Philip H Gutin
Journal:  Neurosurgery       Date:  2018-06-01       Impact factor: 4.654

10.  Multiple extracranial metastases of atypical meningiomas.

Authors:  Gyu-Chan Lee; Seung-Won Choi; Seon-Hwan Kim; Hyon-Jo Kwon
Journal:  J Korean Neurosurg Soc       Date:  2009-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.